Device-Activated Drugs, An Old Dog With Some New Tricks
As technologies move from the lab to commercialization, changes to them need to be made to make them financially and practically appropriate for clinical settings. In Vivo spoke to two companies pioneering new types of device-activated drugs to learn about these changes and how the end products will help patients.
You may also be interested in...
Medtech Insight's Approvals Tracker reports 22 medical device approvals from outside the United States in November, including 12 CE marks from Europe, plus approvals from Taiwan, Singapore, Japan, India, Canada, Australia and Argentina.
The Belgian start-up is developing a scleral contact lens with an inbuilt LCD screen capable of filtering light – offering a non-surgical solution to a variety of ophthalmic conditions.
The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.